European Patent Issued for Human and Pet Anti-Obesity Vaccine to Braasch Biotech

European Patent issued in the United Kingdom for anti-obesity vaccine technologies. Applications for human and pet therapeutic vaccines to treat adult onset obesity.

European Patent Issued for Human and Pet Anti-Obesity Vaccine to Braasch Biotech
Garretson, SD, July 14, 2017 --( Braasch Biotech LLC, a leader in the field of anti-hormone vaccine technologies and applications, announced the issue of a new European Patent in the company’s Somatovac® vaccine portfolio. The new patent, Patent Number EP (UK) 22991194, is entitled “Compositions and Methods for Enhanced Somatostatin Immunogenicity” and issued February 22, 2017. The patent includes claims for the first therapeutic treatment of human and pet obesity by vaccination.

The prevalence of human obesity has risen dramatically in the past decade and is a very serious worldwide health problem. Obesity is a risk factor for high blood pressure, heart disease, stroke, gall bladder disease, breast cancer, prostate cancer, colon cancer, and type-2 diabetes. According to the WHO, currently 1 in 5 adults is overweight with at least a third of them obese. By the year 2030, at least one half of the US population will be obese, if current trending persists.

"Like human obesity, obesity in dogs and cats is at epidemic proportions. Although prevention is always the best option, once an animal reaches the obese state, owner intervention is necessary for the pet’s continued quality of life and longevity. Currently there are no commercially available therapeutic treatments for both dogs and cats," stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. "We are now pleased the European Patent Office also has recognized the vaccine’s novelty and commercial utility in the fight against obesity."

An increasing tendency to overfeed pets, coupled with a lack of exercise or sedentary life style, has resulted in increasing obesity in pets globally. Obesity has been negatively impacting the health of both dogs and cats, making them susceptible to more diseases, therefore driving the demand for animal medicines.

The Association of Pet Obesity Prevention (APOP) has estimated more than 52% of dogs and 57% of cats in the US are overweight or obese. With health concerns becoming more prominent, demand for advanced drugs is also increasing. For example, anti-obesity treatments are in the top 3 growth drivers in companion animal drug markets in North America, Europe, Japan and Latin America.

The European Patent Allowance joins previous patent grants in the United States, Israel, Japan, Mexico, Russia, South Korea, China, the Philippines, Australia, New Zealand and South Africa.

About Braasch Biotech
Braasch Biotech has pioneered a novel field of therapeutic approaches utilizing Somatovac® technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, Growth Hormone deficiencies and obesity treatments. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.

For more information on Braasch Biotech, please email or visit
Braasch Biotech LLC
Keith Haffer
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256